Titan Investment Management LLC Makes New $4.43 Million Investment in Eli Lilly and Company $LLY

Titan Investment Management LLC acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 3,831 shares of the company’s stock, valued at approximately $4,433,000. Eli Lilly and Company comprises about 3.3% of Titan Investment Management LLC’s holdings, making the stock its 8th largest holding.

Other large investors also recently bought and sold shares of the company. Bank of America Corp DE bought a new position in Eli Lilly and Company during the 2nd quarter valued at about $13,522,666,000. Jupiter Topco LLC purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at about $4,667,180,000. Fifth Third Bancorp grew its stake in shares of Eli Lilly and Company by 321.3% in the first quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock worth $1,805,959,000 after acquiring an additional 1,497,423 shares during the period. Corient Private Wealth LP bought a new stake in shares of Eli Lilly and Company in the second quarter worth approximately $764,116,000. Finally, Diamant Asset Management Inc. grew its stake in shares of Eli Lilly and Company by 119,923.8% in the first quarter. Diamant Asset Management Inc. now owns 1,070,612 shares of the company’s stock worth $107,061,000 after acquiring an additional 1,069,720 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Royal Bank Of Canada reissued an “outperform” rating and set a $1,500.00 price target on shares of Eli Lilly and Company in a report on Monday, October 12th. Guggenheim boosted their price target on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a research note on Friday, September 18th. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Thursday, October 1st. Finally, Sanford C. Bernstein upped their price objective on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $1,317.93.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Manufacturing expansion supports long-term growth. Lilly broke ground on a $5 billion facility in Goochland County, Virginia, its first U.S. site designed to produce both active pharmaceutical ingredients and finished medicines. The project is part of a more than $50 billion U.S. manufacturing expansion and is expected to create 650 jobs, improving supply capacity for next-generation cancer and other complex medicines. Lilly Richmond manufacturing facility announcement
• Positive Sentiment: Weight-loss drug demand remains a major growth driver. Analysts expect emerging-market sales of weight-loss drugs to become a significant opportunity, supporting the long-term outlook for Mounjaro, Zepbound and related incretin products. Lilly’s recent growth has been driven by increasing volume, even as pricing has declined. JP Morgan emerging-market weight-loss drug outlook
• Positive Sentiment: Some analysts are raising earnings expectations. Erste Group Bank increased its FY2027 EPS forecast for Lilly to $47.77 from $47.30, signaling confidence in the company’s longer-term earnings trajectory. Erste Group Bank EPS estimate update
• Neutral Sentiment: ESG progress may support the company’s reputation but is unlikely to drive near-term trading. Lilly was cited for combining philanthropy with environmental initiatives while maintaining rapid commercial growth. Eli Lilly sustainability leadership article
• Negative Sentiment: Near-term earnings risk is weighing on sentiment. Previews anticipate a decline in third-quarter earnings, raising concerns that the stock’s elevated valuation leaves limited room for disappointment ahead of the upcoming report. Lilly Q3 earnings preview
• Negative Sentiment: Institutional trimming adds selling pressure. Polen Capital reduced its position in Lilly during the third quarter, although it reportedly maintained confidence in the company’s outlook. Polen Capital trims Lilly position

Eli Lilly and Company Trading Down 2.4%

Shares of Eli Lilly and Company stock opened at $1,275.50 on Friday. The company has a market capitalization of $1.20 trillion, a P/E ratio of 42.80, a P/E/G ratio of 1.70 and a beta of 0.46. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The company has a fifty day moving average of $1,186.64 and a 200 day moving average of $1,120.24. Eli Lilly and Company has a fifty-two week low of $809.63 and a fifty-two week high of $1,321.21.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. Eli Lilly and Company’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 33.22 earnings per share for the current fiscal year.

Insider Activity at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares of the company’s stock, valued at $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.